HMN 2025: How Risk for dementia, ischemic stroke, mortality decrease with GLP-1 receptor agonists in sort 2 diabetes, weight problems

For adults with sort 2 diabetes and weight problems, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are related to a decrease danger for dementia, stroke, and all-cause mortality in contrast with different antidiabetic medicine, based on a research published on-line July 15 in JAMA Network Open.

Huan-Tang Lin, M.D., Ph.D., from Chang Gung Memorial Hospital at Linkou in Taiwan, and colleagues examined the affiliation of semaglutide and tirzepatide with the incidence of dementia, Parkinson illness, ischemic stroke, intracerebral hemorrhage, and all-cause mortality in comparison with different antidiabetic medicine in a retrospective cohort study analyzing digital well being record-based information for adults aged 40 years or older with sort 2 diabetes and weight problems.

The study included 60,860 adults with sort 2 diabetes and weight problems: 30,430 within the GLP-1 RA group and 30,430 within the different antidiabetic drug group (biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, and ?-glucosidase inhibitors) after propensity rating matching.

The researchers discovered that GLP-1 RA customers had a decrease danger for dementia, ischemic stroke, and all-cause mortality throughout a seven-year follow-up (hazard ratios, 0.63, 0.81, and 0.70, respectively), whereas no vital variations had been seen within the dangers for Parkinson illness or intracerebral hemorrhage. Greater advantages had been seen for these aged 60 years or older, girls, and sufferers with a physique mass index of 30 to 40 kg/m².

“These findings spotlight the doable function of GLP-1 RAs in mitigating neurodegenerative and cerebrovascular dangers on this high-risk inhabitants,” the authors write.

© 2025 .